Humanized monoclonal anti-CD20 has impressive activity and radioimmunoconjugates. Targeting the same molecule has led to prolonged remissions in both moderate and myeloablative doses. Idiotype-based vaccination has produced an apparent prolongation in disease-free and overall survival in selected patients with follicular lymphoma. Adoptive cellular therapy is active in the setting of Epstein-Barr virusndash;induced lymphoma after allogeneic bone marrow transplantation. Improvements in each of these developments are readily in sight.
展开▼
